Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma.

Trial Profile

Assessment of Tumor Perfusion Changes in Response to Pazopanib in Renal Cell Carcinoma.

Completed
Phase of Trial: Phase 0

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Sep 2016 Status changed from recruiting to completed.
    • 27 Aug 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 25 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top